That device is by no means expensive in a healthcare context. For example, MRI machines cost around €1–2 million apiece, and there are several hundred of them in Finland alone. You can get Nexstim’s therapy system for somewhere around €200,000, so the cost is quite modest. Unlike its competitors, Nexstim’s NBS 6 also features precise navigation and an intuitive user interface, making it quick and easy to train a nurse to operate the system—so staffing costs won’t break the equation either. Operating the device truly requires only one person’s labor (vs. an MRI, which requires roughly 3–6 person-years of labor per machine).
A person suffering from treatment-resistant major depression costs Finnish society an average of €20,280 per year (source below).
The economic lifespan of Nexstim’s device is 7 years, and disposable costs are around 10% of the purchase price.
Adding this all up, you reach a point where treating just a few patients a year already makes it a profitable endeavor.
Well, this is trying to be that cheaper alternative to the current medications, which don’t even help a large portion of patients—though they certainly can cause side effects.
It would definitely be interesting to hear what you know about those treatments you estimate are coming. What stage might they be at already, or is it some kind of home-care device or something similar?
Yes, the benefits of the treatment are clear to me, and I make referrals when the medical indication is met and it otherwise makes clinical sense. No matter how many cost benefits it brings to society, it doesn’t necessarily show up in the wellbeing services county’s coffers, and in the current austerity cycle, psychiatric care is more likely to face cuts than receive additional investment. In this equation, it’s hard to get more resources to implement rTMS treatment no matter how hard you try. A new device would require more trained staff, as would the option of using the same device to provide treatment in both morning and evening shifts.
I see acquiring the devices as being just as sensible as you do, but society prioritizes other things over depression treatment. I would love to see the mental health time bomb become one of the main themes in the upcoming elections, but I’m not holding my breath. Psychiatry is largely under-resourced, just like primary healthcare, in 21st-century Finland.
Referring to the discussion above, one shouldn’t forget that rather than therapy devices, Nexstim’s largest and fastest-growing business segment is in diagnostics, which Brainlab’s sales organization is currently expanding at a solid pace. On the therapy side as well, the market has already opened up significantly outside Finland, so I personally won’t get depressed (pun intended), even though the cost pressures on Finland’s wellbeing services counties are high and investments may be tight.
Therefore, I don’t see any competing treatment displacing Nexstim’s therapy devices in the near future at least, and I remain confident in the company. In the future, I expect entirely new market openings through Brainlab, and I especially hope for Sinaptica’s success, which I believe would be the biggest catalyst. If nothing substantially changes in the story, I will happily continue putting my pennies into the company’s shares going forward.
Hardly, here’s a brief excerpt from their LinkedIn:
While HOPE did not meet its primary endpoint in the overall mild-to-moderate Alzheimer’s population, results from the prespecified mild subgroup showed consistent slowing of cognitive and functional decline across five clinical measures compared with sham.
In the prespecified mild subgroup, Cognito’s investigational Spectris® therapy was associated with:
• 56% slowing of decline in daily function (ADCS-ADL)
• 47% slowing of decline in cognition and function (CDR-SB)
So, anyone can interpret this for themselves; the truth will likely become clear in the future. Good for Sinaptica that stimulation yields results. Could it be that targeted stimulation, immediate response measurement, and adjustment (i.e., personalization) would produce even better results? Time will probably tell the truth about this as well. For the rest of us, it’s just guesswork at this stage.
If one had the energy, they could compare those Cognito results (Ph2 vs Ph3) with Sinaptica’s results (Ph2). Maybe someone younger than me who’s good with AI??